Uptake of oncology-related biosimilars: a global analysis of usage data
Oncology-related biosimilar uptake in the USA was below-average among included countries. Increasing biosimilar uptake may reduce spending, and savings can be reinvested into cancer care. Future research on time trends can help assess barriers and enablers of biosimilar uptake across countries.
Authors
- Carlo DeAngelis (ORCID: https://orcid.org/0000-0001-7109-4620)
- Kelvin Chan (ORCID: https://orcid.org/0000-0002-2501-3057)
- Mina Tadrous (ORCID: https://orcid.org/0000-0003-1911-6129)
- Martin Ho (ORCID: https://orcid.org/0000-0001-5160-0776)
- Jianyuan Chai (ORCID: https://orcid.org/0000-0001-6975-6867)
- Shanzeh Chaudhry
Institutions
- Sunnybrook Health Science Centre (CA)
- 3M (United States) (US)
- University of Pittsburgh (US)
- University of Toronto (CA)
- Health Sciences Centre (CA)
- Canadian Centre for Applied Research in Cancer Control (CA)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-11-16
- DOI
- https://doi.org/10.1093/jnci/djaf335
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00